Genmab A/S
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Genmab A/S
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Genmab A/S stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Genmab A/S by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Genmab A/S is GMAB:xcse. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Genmab A/S has its primary listing on NASDAQ OMX Copenhagen. You can trade Genmab A/S with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Genmab A/S is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Genmab A/S as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Genmab A/S.